India's pharma sector at a crossroads.

India's pharma sector at a crossroads. Dr. Reddy's Co-Chairman G.V. Prasad delivers a stark assessment: India remains the generic pharmacy of the world, not the pharmacy of the world. That distinction reveals a critical gap. While the country excels in producing affordable generics, it lags in drug discovery and development. Prasad highlights underfunded innovation pipelines and missed acquisition opportunities as key challenges. The company is now pivoting toward innovation-led growth with concrete targets and timelines. On artificial intelligence, he remains pragmatic, viewing it as marginally helpful rather than transformational. This shift signals the Indian pharma industry's urgent need to move beyond incremental gains and compete globally in high-value drug development.